Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + ibrutinib + venetoclax
- Development stage
- Phase 2
- Lead developer
- Genmab
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a **combination therapy** under clinical investigation for the treatment of chronic lymphocytic leukemia (CLL) and potentially related lymphoid malignancies. The regimen comprises: - **Epcoritamab:** a bispecific monoclonal antibody that targets both CD3 (on T cells) and CD20 (on B cells), facilitating T-cell mediated cytotoxicity of malignant B cells. - **Ibrutinib:** an oral small molecule inhibitor of Bruton's tyrosine kinase (BTK), interrupting B-cell receptor signaling and reducing proliferation and survival of B-cell malignancies. - **Venetoclax:** a selective small molecule inhibitor of BCL-2, promoting apoptosis in malignant B cells. This combination is designed to target malignant B cells with complementary mechanisms: direct immune-mediated cytotoxicity (epcoritamab), inhibition of survival/proliferation pathways (ibrutinib), and induction of apoptosis (venetoclax). Early-phase clinical and preclinical research supports superior cytotoxicity against CLL cells, including in settings with BTKi resistance. It is not an approved regimen but is under clinical investigation, most notably for relapsed/refractory CLL and high-risk cases[1][4][6].
- Other names
- epcoritamab + ibrutinib + venetoclax
02
Targets
BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on epcoritamab + ibrutinib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + ibrutinib + venetoclax.